These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 27153215

  • 1. A shot at AIDS.
    Koff WC.
    Curr Opin Biotechnol; 2016 Dec; 42():147-151. PubMed ID: 27153215
    [Abstract] [Full Text] [Related]

  • 2. HIV/AIDS: vaccines and alternate strategies for treatment and prevention.
    Voronin Y, Phogat S.
    Ann N Y Acad Sci; 2010 Sep; 1205 Suppl 1():E1-9. PubMed ID: 20860672
    [Abstract] [Full Text] [Related]

  • 3. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
    Ahmad M, Ahmed OM, Schnepp B, Johnson PR.
    Annu Rev Virol; 2017 Sep 29; 4(1):491-510. PubMed ID: 28645240
    [Abstract] [Full Text] [Related]

  • 4. Antibodies in HIV-1 vaccine development and therapy.
    Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC.
    Science; 2013 Sep 13; 341(6151):1199-204. PubMed ID: 24031012
    [Abstract] [Full Text] [Related]

  • 5. HIV Vaccines: One Step Closer.
    Low MSY, Tarlinton D.
    Trends Mol Med; 2017 Jan 13; 23(1):1-3. PubMed ID: 27889424
    [Abstract] [Full Text] [Related]

  • 6. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S, Clark ES, Termini JM, Boucher J, Kanagavelu S, LeBranche CC, Abraham S, Montefiori DC, Khan WN, Stone GW.
    J Virol; 2015 Apr 13; 89(8):4158-69. PubMed ID: 25631080
    [Abstract] [Full Text] [Related]

  • 7. Advances in HIV-1 Vaccine Development.
    Gao Y, McKay PF, Mann JFS.
    Viruses; 2018 Apr 01; 10(4):. PubMed ID: 29614779
    [Abstract] [Full Text] [Related]

  • 8. The 2017 Keystone Symposium on HIV Vaccines.
    Cottrell CA, Ward AB.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2348-2351. PubMed ID: 28786733
    [No Abstract] [Full Text] [Related]

  • 9. Prospects for vaccine protection against HIV-1 infection and AIDS.
    Letvin NL, Barouch DH, Montefiori DC.
    Annu Rev Immunol; 2002 Oct 03; 20():73-99. PubMed ID: 11861598
    [Abstract] [Full Text] [Related]

  • 10. HIV/AIDS Vaccines: 2018.
    Robinson HL.
    Clin Pharmacol Ther; 2018 Dec 03; 104(6):1062-1073. PubMed ID: 30099743
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y, Tian M, Gao Y.
    AIDS Res Ther; 2017 Sep 12; 14(1):50. PubMed ID: 28893278
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T.
    Curr Opin Mol Ther; 2003 Feb 12; 5(1):25-32. PubMed ID: 12669467
    [Abstract] [Full Text] [Related]

  • 15. Current progress in the development of a prophylactic vaccine for HIV-1.
    Gamble LJ, Matthews QL.
    Drug Des Devel Ther; 2010 Dec 22; 5():9-26. PubMed ID: 21267356
    [Abstract] [Full Text] [Related]

  • 16. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, Cafaro A, Francavilla V, Moretti S, Pavone Cossut MR, Collacchi B, Arancio A, Paniccia G, Casabianca A, Magnani M, Buttò S, Levendal E, Ndimande JV, Asia B, Pillay Y, Garaci E, Monini P, SMU-MeCRU study group.
    Retrovirology; 2016 Jun 09; 13(1):34. PubMed ID: 27277839
    [Abstract] [Full Text] [Related]

  • 17. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines.
    Koff WC, Russell ND, Walport M, Feinberg MB, Shiver JW, Karim SA, Walker BD, McGlynn MG, Nweneka CV, Nabel GJ.
    Vaccine; 2013 Apr 18; 31 Suppl 2():B204-8. PubMed ID: 23598483
    [Abstract] [Full Text] [Related]

  • 18. Closing the door to human immunodeficiency virus.
    Kang Y, Guo J, Chen Z.
    Protein Cell; 2013 Feb 18; 4(2):86-102. PubMed ID: 23479426
    [Abstract] [Full Text] [Related]

  • 19. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
    Choi E, Michalski CJ, Choo SH, Kim GN, Banasikowska E, Lee S, Wu K, An HY, Mills A, Schneider S, Bredeek UF, Coulston DR, Ding S, Finzi A, Tian M, Klein K, Arts EJ, Mann JF, Gao Y, Kang CY.
    Retrovirology; 2016 Nov 28; 13(1):82. PubMed ID: 27894306
    [Abstract] [Full Text] [Related]

  • 20. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S, Suscovich TJ, Alter G.
    Annu Rev Med; 2016 Nov 28; 67():185-200. PubMed ID: 26565674
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.